Akebia Therapeutics, INC

Akebia Therapeutics and U.S. Renal Care announce the VOICE trial met its primary composite endpoint, demonstrating non-inferiority and superiority of Vafseo versus standard-of-care ESA.

Akebia Therapeutics reported Q1 2026 financial results, showing Vafseo net product revenues of $15.8 million and a 60% increase in treated patients, alongside progress in its kidney disease pipeline.

Akebia Therapeutics strengthens its Board of Directors with the appointment of biopharmaceutical leader Philip Vickers, Ph.D., following the retirement of Steven C. Gilman, Ph.D.

Akebia Therapeutics announced robust financial results for Q4 and full-year 2025, driven by significant Vafseo revenue growth and pipeline advancements.

Akebia Therapeutics has signed a new lease for its corporate headquarters and laboratory space in Waltham, Massachusetts, and updated severance agreements for its CEO and CFO.

Akebia Therapeutics announced key corporate updates for its Vafseo commercial business and provided an outlook on upcoming milestones for its mid-stage rare kidney disease pipeline, including expected Q4 2025 Vafseo net product revenue.

Akebia Therapeutics reported a decrease in net product revenue for the first quarter of 2026, primarily driven by lower Auryxia sales, partially offset by increased Vafseo revenue.

Akebia Therapeutics reported a return to net income and significant revenue growth for the nine months ended September 30, 2025, driven by the successful U.S. launch of Vafseo, despite the loss of exclusivity for Auryxia.

Akebia Therapeutics reported a significant financial turnaround, achieving net income and substantial revenue growth driven by the successful U.S. launch of Vafseo, despite Auryxia's loss of exclusivity.

Akebia Therapeutics achieves profitability in Q1 2025, driven by the launch of Vafseo and increased Auryxia sales, while navigating Auryxia's loss of exclusivity.

Akebia Therapeutics reports a net loss of $20 million for Q3 2024, with product revenue declining, while preparing for the launch of Vafseo and facing Auryxia's loss of exclusivity.

Akebia Therapeutics reports a net loss of $8.6 million for Q2 2024, with product revenue of $41.2 million, while preparing for the U.S. launch of Vafseo in January 2025.

Akebia Therapeutics saw significant revenue growth in 2025, primarily from the U.S. launch of Vafseo, while navigating generic competition for Auryxia and advancing its rare kidney disease pipeline.

Akebia Therapeutics details its 2024 financial performance, emphasizing the U.S. launch of Vafseo and advancements in its research and development pipeline.

Akebia Therapeutics files its 10-K, detailing a warrant agreement, financial performance, and strategic initiatives.

Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, Inc., reported a transaction involving the sale of 56,019 shares of common stock on June 29, 2026.

Philip J. Vickers, a Director at Akebia Therapeutics, Inc., reported the acquisition of stock options under the company's 2023 Plan.

Akebia Therapeutics CEO John P. Butler acquired 69,270 shares of common stock, simultaneously resolving a short-swing profit issue related to a prior sell-to-cover transaction.

Akebia Therapeutics' SVP and Chief Accounting Officer, Richard C. Malabre, sold shares to cover tax withholding obligations related to RSU vesting.

Akebia Therapeutics' Chief Commercial Officer, Nicholas Grund, sold 84,829 shares of common stock to cover tax withholding obligations related to RSU vesting.

Akebia Therapeutics' Chief Medical Officer, Steven Burke, sold 67,658 shares of common stock for tax withholding purposes related to RSU vesting.

Akebia Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, and proposes a significant increase in authorized common stock.

Akebia Therapeutics, Inc. will hold its annual meeting virtually on June 10, 2025, with several key proposals for shareholders to vote on.

Akebia Therapeutics is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance and make other changes.

Akebia Therapeutics will hold its annual meeting on June 6, 2024, featuring proposals including director elections, stock incentive plan amendments, executive compensation, and auditor ratification.

Akebia Therapeutics is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance by 9,800,000.

State Street Corporation has reported beneficial ownership of 4.3% of Akebia Therapeutics Inc. common stock as of March 31, 2026.

The Vanguard Group reported a 0% beneficial ownership in Akebia Therapeutics Inc. following an internal realignment.

State Street Corporation has reported a 5.2% beneficial ownership stake in Akebia Therapeutics Inc., holding 13,687,561 common shares as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.2% beneficial ownership stake in Akebia Therapeutics Inc., totaling 19,219,819 common shares.

The Vanguard Group has reported a 5.37% beneficial ownership stake in Akebia Therapeutics Inc., holding 12,685,803 common shares as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.1% passive ownership stake in Akebia Therapeutics Inc. as of March 31, 2025.